Clinical Trials Sponsored by NervGen Pharma

Total 8690 results

LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
LEO Pharma

Completed

PSOREAL - Managing PSOriasis in the REAL World (PSOREAL)

Psoriasis Vulgaris

United Kingdom, Canada, Sweden
Zealand Pharma

Completed

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

United States
SCF Pharma

Completed

Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)

Healthy Adults

Canada
Pharma 2100

Withdrawn

Healing of Ischemic Leg Ulcers in Patients Treated With iSONIAzid (SONIA)

Arterial Leg Ulcer

Denmark
MaaT Pharma

Completed

Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer (HERACLES)

Fecal Microbiota Transplantation

France, Italy, Poland
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Atopic Dermatitis

United States, Germany, Belgium, Canada, Spain, United Kingdom, Poland, Netherlands
Innate Pharma

Completed

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Cutaneous T-Cell Lymphoma

United States, France, Netherlands, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
Getz Pharma

Completed

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus (SAFE-PAK)

Type II Diabetes Mellitus

Pakistan
Amryt Pharma

Enrolling by invitation

Global Lomitapide Pregnancy Exposure Registry

Pregnancy

Germany
Hilton Pharma

Unknown

Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020

Covid-19

Pakistan
HRA Pharma

Completed

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome (PROMPT)

Cushing's Syndrome

Germany, Belgium, Italy, Hungary, Poland, Romania, Spain, Turkey
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Healthy | NASH - Nonalcoholic Steatohepatitis

Australia
LEO Pharma

Completed

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

Actinic Keratosis (AK)

Germany, United Kingdom, France
UCB Pharma

Completed

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

Epilepsy, Partial

Hong Kong, Malaysia, Philippines, Singapore, Taiwan, Thailand
Petra Pharma

Unknown

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer
pH Pharma

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy Subjects

Healthy Volunteer

United States
UCB Pharma

Completed

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, Estonia, Finland, France, Hungary, Israel, Latvia, Lithuania, Mexico, New Zealand, Russian Federation, Serbia, Slovakia, Ukraine
Getz Pharma

Completed

Knowledge and Practices of ADR Reporting in LMICs

Adverse Reaction

Pakistan
LEO Pharma

Completed

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Psoriasis Vulgaris

Germany
UCB Pharma

Completed

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

Arthritis | Rheumatoid Arthritis

United States, Germany
Innate Pharma

Terminated

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Chronic Lymphocytic Leukemia

United States
LEO Pharma

Completed

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study (BODYGUARD)

Psoriasis Vulgaris

Russian Federation
LEO Pharma

Completed

PMS to Evaluate the Safety and Efficacy of Picato® Gel

Actinic Keratosis

Korea, Republic of
LEO Pharma

Completed

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

Psoriasis Vulgaris

France
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
Inventiva Pharma

Completed

A Study in MPS VI to Assess Safety and Efficacy of Odiparcil (iMProveS)

Mucopolysaccharidosis VI

United Kingdom, France, Germany, Portugal
HRA Pharma

Completed

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella (ellipseII)

Emergency Contraception

United States
LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
Kibow Pharma

Completed

Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure (Probiotics)

Chronic Kidney Failure

United States
PLx Pharma

Completed

Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Bioequivalence
LEO Pharma

Completed

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
UCB Pharma

Completed

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Psoriasis

France, Germany
UCB Pharma

Completed

Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Chronic Plaque Psoriasis

France, Germany
LEO Pharma

Completed

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Actinic Keratosis

United States
UCB Pharma

Completed

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Epilepsy

United States, Belgium, Mexico
Inventiva Pharma

Completed

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (FASST)

Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis

United Kingdom, France, Spain, Switzerland, Italy, Slovenia, Netherlands, Germany, Bulgaria, Poland
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Innate Pharma

Completed

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) (EFFIKIR)

Acute Myeloid Leukemia

France
LEO Pharma

Completed

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Netherlands, Poland, Romania
LEO Pharma

Completed

A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas

Psoriasis Vulgaris

France
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

Germany
LEO Pharma

Completed

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada, France
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
UCB Pharma

Completed

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4)

Systemic Lupus Erythematosus

United States, Brazil, Canada, France, Germany, Hungary, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom, Australia, Belgium, Bulgaria, Czechia, Estonia, Israel, Korea, Republic of, T... and more
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Actinic Keratosis

United States

3

Subscribe